Navigation Links
Cell-death receptor links cancer susceptibility and inflammation
Date:12/27/2007

PHILADELPHIA - For over 10 years, Wafik S. El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology at the University of Pennsylvania School of Medicine, has been pursuing a cancer-targeting molecule called TRAIL and its molecular partners. TRAIL is normally produced by immune cells and curtails tumor spread by binding to a specialized receptor on a tumors surface.

However, in cancer patients who often have suppressed immunity, and for reasons we still dont understand, there isnt enough TRAIL being produced, so tumors are not suppressed, explains El-Deiry, who is also Co-Program Leader of the Radiation Biology Program for the Abramson Cancer Center at Penn.

Most recently, El-Deiry and colleagues demonstrated for the first time a link between TRAILs receptor and cancer susceptibility, as reported online December 13, 2007 in the Journal of Clinical Investigation in advance of the January 2008 print issue. Unexpectedly, they also found a connection via Trail between inflammation and cancer susceptibility.

Mice engineered without the TRAIL receptor on their cells versus healthy controls developed larger and more tumors in their livers and other organs after being challenged with a chemical carcinogen or radiation. The team also bred TRAIL receptor knock-out mice with mice genetically engineered to get B-cell lymphomas that metastasize to the liver. Their offspring displayed more liver tumors compared to controls. This is the first direct in vivo evidence that loss of the tumor death-inducing TRAIL receptor confers cancer susceptibility, says El-Deiry.

When intact, TRAIL and its receptor decrease the influx of inflammatory cells and molecules that can lead to cancer. New models of cancer have suggested a link between inflammation and cancer in the last five years, and El-Deiry is in the early stages of trying to understand this connection with respect to the TRAIL pathway.

For example, in this study, the mice without the TRAIL receptor that were irradiated developed chronic pneumonia, an inflammatory response, as well tumors, evidence pointing to the connection between cancer and inflammation via TRAIL. One benefit of this work is that it provides a new and unanticipated model implicating a TRAIL pathway deficiency in the chronic toxicity of radiation therapy, he notes. Inflammation is a common late and serious side-effect of radiation treatment in people.

El-Deiry and his team are now looking within tumor tissue for inflammatory molecules as clues to how cancer and inflammation are coupled. Our work with TRAIL and its receptor in mouse models represents a new way to look at cancer susceptibility and its potential therapy in humans as well as new ways to decrease debilitating radiation side-effects experienced by cancer patients, says El-Deiry.

Co-authors in addition to El-Deiry are Niklas Finnberg from Penn and Andres J.P. Klein-Szanto from Fox Chase Cancer Center, Philadelphia. This research was funded in part by the National Cancer Institute.

This release can be found at www.pennhealth.com/news.


'/>"/>
Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
3. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
4. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
5. Food restriction increases dopamine receptor levels in obese rats
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
8. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
9. Receptor protein appears to be key in breakdown of kidney filtration
10. Pathway links inflammation, angiogenesis and breast cancer
11. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... 23, 2017  The U.S. Food and Drug Administration ... treatment of adults and pediatric patients 12 years and ... who have not received prior chemotherapy. This is the ... form of skin cancer. "While skin cancer ... a rare form called Merkel cell cancer have not ...
(Date:3/23/2017)... SAN DIEGO and VANCOUVER, British ... Inc. (NASDAQ: SPHS ) (the "Company" or ... for the treatment of urological diseases, today announced that ... which evaluated the drug as a focal treatment for ... on March 26, 2017 at the 32 nd ...
Breaking Medicine Technology: